Including the excluded
The reported prevalence and incidence of thrombocytopenia among patients with ACS has varied depending on the definition and the nature of the study. Observational evidence suggests that baseline thrombocytopenia, defined as a platelet count of <150 Â 10 9 /L, is present in approximately 5% of ACS patients, 6, 7 whereas incident thrombocytopenia can be expected in 13% of patients. 6 Incident thrombocytopenia can be seen more frequently in patients who are older or have diabetes, renal insufficiency, heart failure, or prior cardiovascular disease. 6 Despite making up a substantial proportion of ACS patients in clinical practice, these patients have been excluded or under-represented in important clinical trials evaluating antiplatelet therapies in ACS patients. Patients with thrombocytopenia were excluded from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, 8 the PLATelet inhibition and patient Outcomes (PLATO) trial, 9 the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON (CHAMPION) PHOENIX trial, 10 and represented only 0.8% of the participants in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial.
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Prognostic implications
The presence of thrombocytopenia in ACS patients predicts significantly worse outcomes. 6, 7 Yadav et al. examined the implication of baseline thrombocytopenia on clinical outcomes in 10 603 patients who underwent percutaneous coronary intervention (PCI) for non-ST-elevation ACS (NSTE-ACS) or ST-elevation myocardial infarction (STEMI) pooled from two large-scale randomized trials. 7 In multivariable analysis, the presence of thrombocytopenia at baseline was an independent predictor of mortality at 1 year [hazard ratio (HR), 1. 4.12) . Every 10% decrease in platelet count was associated with increased mortality (adjusted ORs: 1.39, 95% CI: 1.33 to 1.46 ) and bleeding risk (adjusted OR: 1.89, 95% CI: 1.83 to 1.95 ). Ominously, approximately one in four patients who developed moderate/severe thrombocytopenia did not survive the hospitalization. 6 The influence of the aetiology of thrombocytopenia on prognosis and treatment has not been well investigated and warrants exploration. Liver disease in particular is associated with coagulation disorders as well and therefore may carry even greater bleeding risk in the setting of thrombocytopenia. The association of thrombocytopenia and increased ischaemic events remains poorly understood. It may reflect the presence of a greater degree of comorbidities that are unmeasured. Some authors have suggested that thrombocytopenia in ACS may reflect a greater burden of atherosclerosis predisposing to heightened platelet consumption, or reflect clinically significant thrombosis, and consequently, its presence should be viewed as a marker of disease severity.
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Management strategies and future directions
Has this common and high-risk group of patients been neglected by the research community to date? This appears to be the case, with an absence of evidence to guide physicians on the management of this cohort leading to a sense of despair amongst clinicians, as summarized by Warkentin et al. in an editorial 'We know that thrombocytopenia is bad, but we do not think we can do anything about it '. 12 It is our belief that positive steps can be made and should begin with randomized clinical trials evaluating the safety and efficacy of various antiplatelet regimens in this cohort.
A comparative study of DAPT vs. aspirin or P2Y 12 inhibitor monotherapy in ACS patients with thrombocytopenia would be valuable. Sub-analysis of patients with varying degrees of thrombocytopenia would help determine the platelet count at which these regimens reach a 'tipping point', where the bleeding risk outweighs any ischaemic benefit. Of the P2Y 12 inhibitors, clopidogrel offers a lower 10 However, patients with a platelet count of <100 Â 10 9 /L were excluded from this trial. As such, the bleeding risk associated with cangrelor might be significant if used in patients with platelets below this threshold. Nevertheless, an investigation of cangrelor in the inpatient setting as both monotherapy or as part of a combination regimen in this cohort might be worthwhile.
Thrombocytopenia can generally be classified as mild, moderate, or severe ( Table 1) . While a patient's risk of bleeding can increase 
even with mild thrombocytopenia, 6 we believe a platelet count of <100 Â 10 9 /L is clinically relevant, and warrants proactive measures to reduce the risk of bleeding ( Table 2) . What approach could clinicians take until further randomized trial evidence is available? We believe initial management should begin with identification and correction of any reversible causes of thrombocytopenia. If suspected as the instigating factor, medications associated with the development of thrombocytopenia such as unfractionated heparin, glycoprotein IIb/IIIa inhibitors, furosemide, NSAIDs, and penicillinbased antibiotics should be discontinued.
It is our opinion that clopidogrel monotherapy should be administered to ACS patients with thrombocytopenia who are not undergoing PCI if their platelet count is <100 Â 10 9 /L but > _50 Â 10 9 /L and in the absence of bleeding (Figure 2) . We suggest clopidogrel as opposed to aspirin monotherapy based on the results of the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) randomized controlled trial. This trial demonstrated a statistically significant relative risk reduction in gastrointestinal bleeding with clopidogrel 75 mg as opposed to aspirin 325 mg (relative risk reduction of 31.8%, CI: 7.9-49.5, P = 0.012). 13 Due to their association with higher bleeding rates 3 , we propose prasugrel and ticagrelor be avoided in this cohort, though their study as monotherapy, particularly of ticagrelor with its twice daily dosing and reversible binding, would be of great interest. In patients with a platelet count <50 Â 10 9 /L or in the setting of active bleeding, we advise stopping all antiplatelet therapy and avoidance of PCI. The addition of a proton pump inhibitor would likely reduce the rates of gastrointestinal bleeding and would be advised. 14 15, 16 Based on the limited data from these trials, we would recommend that stented patients with ACS who have a platelet count of <100 Â 10 9 /L but > _50 Â 10 9 /L receive DAPT with aspirin and clopidogrel for 1 month followed by a single antiplatelet agent thereafter.
Finally in patients with stable coronary artery disease, in the absence of evidence, we suggest stopping antiplatelet therapy and avoiding PCI in patients with a platelet count <50 Â 10 9 /L. In thrombocytopenic patients with a platelet count > _50 Â 10 9 /L and <100 Â 10 9 /L, we advise clopidogrel monotherapy and a proton pump inhibitor. If a patient's symptoms persist despite three antianginal agents at maximally tolerated doses, then PCI is reasonable after a risk/benefit discussion with the patient (Figure 3) . If PCI is undertaken, we recommend a second generation drug-eluting stent in combination with DAPT with aspirin and clopidogrel for 1 month followed by clopidogrel thereafter, along with a proton pump inhibitor.
